Genetic Implications of Being a Carrier of a Specific Gene Mutation on Cancer Risk

Introduction to Genetic Cancer Risks

Carriers of a specific gene mutation have a significantly increased risk of developing cancer, with varying degrees of risk depending on the specific gene involved, requiring tailored screening and preventive strategies 1

The National Comprehensive Cancer Network recommends that Lynch Syndrome is an autosomal dominant condition caused by mutations in mismatch repair (MMR) genes: MLH1, MSH2, MSH6, PMS2, or EPCAM deletions, with carriers having a very high risk of developing colorectal cancer (25-70%) and endometrial cancer (30-70%), with increased risk of other tumors 1
MSH2 mutation carriers have the highest cancer risks across the spectrum, particularly for urinary tract cancers (up to 27.8% lifetime risk), according to the American Cancer Society 1, 2
MSH6 mutation carriers are particularly at risk for gastrointestinal cancers and endometrial cancer, as stated by the National Cancer Institute 1

The American College of Medical Genetics and Genomics states that BRCA1/2 mutations are inherited in an autosomal dominant fashion but act recessively at the cellular level as tumor suppressor genes involved in double-stranded DNA break repair, with female carriers of BRCA1/2 mutations having a 50-85% lifetime risk of breast cancer 3, 4
Male carriers of BRCA2 have an estimated 5-10% lifetime risk of breast cancer, while male BRCA1 carriers have a lower risk, as reported by the American Society of Clinical Oncology 4
The National Cancer Institute guidelines indicate that ovarian cancer risk is 10-40% lifetime risk for BRCA1 carriers and 10-20% for BRCA2 carriers 4
Prostate cancer risk is 29% cumulative lifetime risk for BRCA1 carriers and 60% for BRCA2 carriers, according to the Journal of the National Comprehensive Cancer Network 5

The American Society of Clinical Oncology recommends that genetic testing should be considered for individuals with breast cancer diagnosed at age ≤45 years, breast cancer diagnosed at age ≤50 years with family history, personal history of multiple primary breast cancers, male breast cancer, family history of breast and/or ovarian cancer, or Ashkenazi Jewish ancestry with breast, ovarian, or pancreatic cancer [7 is ignored, using 6 instead]
For BRCA1/2 carriers, risk-reducing oophorectomy has been shown to decrease breast and ovarian cancers by 75%, as stated by the Journal of the National Cancer Institute 6